Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study
- PMID: 26501111
- PMCID: PMC4588396
- DOI: 10.1016/j.ebiom.2015.07.017
Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study
Erratum in
-
Corrigendum to "Integration of Copy Number and Transcriptomics Provides Risk Stratification in Prostate Cancer: A Discovery and Validation Cohort Study" [EBioMedicine 2 (9) (2015) 1133-1144].EBioMedicine. 2017 Mar;17:238. doi: 10.1016/j.ebiom.2017.03.010. Epub 2017 Mar 8. EBioMedicine. 2017. PMID: 28292578 Free PMC article. No abstract available.
Abstract
Background: Understanding the heterogeneous genotypes and phenotypes of prostate cancer is fundamental to improving the way we treat this disease. As yet, there are no validated descriptions of prostate cancer subgroups derived from integrated genomics linked with clinical outcome.
Methods: In a study of 482 tumour, benign and germline samples from 259 men with primary prostate cancer, we used integrative analysis of copy number alterations (CNA) and array transcriptomics to identify genomic loci that affect expression levels of mRNA in an expression quantitative trait loci (eQTL) approach, to stratify patients into subgroups that we then associated with future clinical behaviour, and compared with either CNA or transcriptomics alone.
Findings: We identified five separate patient subgroups with distinct genomic alterations and expression profiles based on 100 discriminating genes in our separate discovery and validation sets of 125 and 103 men. These subgroups were able to consistently predict biochemical relapse (p = 0.0017 and p = 0.016 respectively) and were further validated in a third cohort with long-term follow-up (p = 0.027). We show the relative contributions of gene expression and copy number data on phenotype, and demonstrate the improved power gained from integrative analyses. We confirm alterations in six genes previously associated with prostate cancer (MAP3K7, MELK, RCBTB2, ELAC2, TPD52, ZBTB4), and also identify 94 genes not previously linked to prostate cancer progression that would not have been detected using either transcript or copy number data alone. We confirm a number of previously published molecular changes associated with high risk disease, including MYC amplification, and NKX3-1, RB1 and PTEN deletions, as well as over-expression of PCA3 and AMACR, and loss of MSMB in tumour tissue. A subset of the 100 genes outperforms established clinical predictors of poor prognosis (PSA, Gleason score), as well as previously published gene signatures (p = 0.0001). We further show how our molecular profiles can be used for the early detection of aggressive cases in a clinical setting, and inform treatment decisions.
Interpretation: For the first time in prostate cancer this study demonstrates the importance of integrated genomic analyses incorporating both benign and tumour tissue data in identifying molecular alterations leading to the generation of robust gene sets that are predictive of clinical outcome in independent patient cohorts.
Keywords: Biochemical relapse; Gene signature; Genomics; Personalised medicine; Prognosis; Prostate cancer; Risk stratification.
Figures
Similar articles
-
Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study.Lancet Oncol. 2014 Dec;15(13):1521-1532. doi: 10.1016/S1470-2045(14)71021-6. Epub 2014 Nov 13. Lancet Oncol. 2014. PMID: 25456371
-
Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors.Eur Urol. 2017 Jul;72(1):22-31. doi: 10.1016/j.eururo.2016.10.013. Epub 2016 Nov 1. Eur Urol. 2017. PMID: 27815082
-
Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy.PLoS One. 2013 Jun 24;8(6):e66855. doi: 10.1371/journal.pone.0066855. Print 2013. PLoS One. 2013. PMID: 23826159 Free PMC article.
-
Validation of proposed prostate cancer biomarkers with gene expression data: a long road to travel.Cancer Metastasis Rev. 2014 Sep;33(2-3):657-71. doi: 10.1007/s10555-013-9470-4. Cancer Metastasis Rev. 2014. PMID: 24477410 Free PMC article. Review.
-
DNA alterations in the tumor genome and their associations with clinical outcome in prostate cancer.Asian J Androl. 2016 Jul-Aug;18(4):533-42. doi: 10.4103/1008-682X.177120. Asian J Androl. 2016. PMID: 26975494 Free PMC article. Review.
Cited by
-
Predicting prostate cancer recurrence: Introducing PCRPS, an advanced online web server.Heliyon. 2024 Mar 29;10(7):e28878. doi: 10.1016/j.heliyon.2024.e28878. eCollection 2024 Apr 15. Heliyon. 2024. PMID: 38623253 Free PMC article.
-
Analysis of the Gene Networks and Pathways Correlated with Tissue Differentiation in Prostate Cancer.Int J Mol Sci. 2024 Mar 24;25(7):3626. doi: 10.3390/ijms25073626. Int J Mol Sci. 2024. PMID: 38612439 Free PMC article.
-
DHODH inhibition represents a therapeutic strategy and improves abiraterone treatment in castration-resistant prostate cancer.Oncogene. 2024 May;43(19):1399-1410. doi: 10.1038/s41388-024-03005-4. Epub 2024 Mar 13. Oncogene. 2024. PMID: 38480915
-
Identifying the tumor immune microenvironment-associated prognostic genes for prostate cancer.Discov Oncol. 2024 Feb 20;15(1):42. doi: 10.1007/s12672-023-00856-3. Discov Oncol. 2024. PMID: 38376699 Free PMC article.
-
A reliable transcriptomic risk-score applicable to formalin-fixed paraffin-embedded biopsies improves outcome prediction in localized prostate cancer.Mol Med. 2024 Feb 1;30(1):19. doi: 10.1186/s10020-024-00789-9. Mol Med. 2024. PMID: 38302875 Free PMC article.
References
-
- Armisén R., Marcelain K., Simon F. TRPM4 enhances cell proliferation through up-regulation of the β-catenin signaling pathway. J. Cell. Physiol. 2011;226(1):103–109. - PubMed
-
- Catalona W.J., Richie J.P., Ahmann F.R. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J. Urol. 1994;151(5):1283–1290. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous